Stem Cell Authority Stock Analysis
| SCAL Stock | USD 0.0001 0.00 0.00% |
Stem Cell Authority has over 675,104 in debt which may indicate that it relies heavily on debt financing. Stem Cell's financial risk is the risk to Stem Cell stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Stem Cell's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Stem Cell's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Stem Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Stem Cell's stakeholders.
For many companies, including Stem Cell, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Stem Cell Authority, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Stem Cell's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Stem Cell's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Stem Cell is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Stem Cell to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Stem Cell is said to be less leveraged. If creditors hold a majority of Stem Cell's assets, the Company is said to be highly leveraged.
Stem Cell Authority is overvalued with Real Value of 8.6E-5 and Hype Value of 1.09E-4. The main objective of Stem Cell pink sheet analysis is to determine its intrinsic value, which is an estimate of what Stem Cell Authority is worth, separate from its market price. There are two main types of Stem Cell's stock analysis: fundamental analysis and technical analysis.
The Stem Cell pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Stem |
Stem Pink Sheet Analysis Notes
The company had not issued any dividends in recent years. Stem Cell Authority had 2:1 split on the 6th of April 2005. Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. The companys technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange.The quote for Stem Cell Authority is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Stem Cell Authority contact Carlzo Cardwell at 330-835-0200 or learn more at https://www.stemcellauthority.com.Stem Cell Authority Investment Alerts
| Stem Cell Authority generated a negative expected return over the last 90 days | |
| Stem Cell Authority has high historical volatility and very poor performance | |
| Stem Cell Authority has some characteristics of a very speculative penny stock |
Stem Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.34 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stem Cell's market, we take the total number of its shares issued and multiply it by Stem Cell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Stem Profitablity
The company has Profit Margin (PM) of 0.55 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.55 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.55.Technical Drivers
As of the 8th of February, Stem Cell has the Risk Adjusted Performance of (0.09), variance of 38.46, and Coefficient Of Variation of (806.23). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stem Cell Authority, as well as the relationship between them. Please validate Stem Cell Authority coefficient of variation and treynor ratio to decide if Stem Cell is priced more or less accurately, providing market reflects its prevalent price of 1.0E-4 per share. As Stem Cell Authority appears to be a penny stock we also recommend to double-check its information ratio numbers.Stem Cell Authority Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Stem Cell price series with the more recent values given greater weights.
Stem Cell Outstanding Bonds
Stem Cell issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Stem Cell Authority uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Stem bonds can be classified according to their maturity, which is the date when Stem Cell Authority has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| STLA 1711 29 JAN 27 Corp BondUS85855CAA80 | View | |
| STLA 2691 15 SEP 31 Corp BondUS85855CAB63 | View | |
| STLA 5625 12 JAN 28 Corp BondUS85855CAD20 | View | |
| STLA 6375 12 SEP 32 Corp BondUS85855CAE03 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Stem Cell Predictive Daily Indicators
Stem Cell intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Stem Cell pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
Stem Cell Forecast Models
Stem Cell's time-series forecasting models are one of many Stem Cell's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Stem Cell's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Stem Cell Authority Debt to Cash Allocation
Many companies such as Stem Cell, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Stem Cell Authority currently holds 675.1 K in liabilities with Debt to Equity (D/E) ratio of 4.88, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Stem Cell Authority has a current ratio of 1.1, suggesting that it may have difficulties to pay its financial obligations when due. Debt can assist Stem Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Stem Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stem Cell Authority sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stem to invest in growth at high rates of return. When we think about Stem Cell's use of debt, we should always consider it together with cash and equity.Stem Cell Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Stem Cell's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Stem Cell, which in turn will lower the firm's financial flexibility.Stem Cell Corporate Bonds Issued
About Stem Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Stem Cell prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Stem shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Stem Cell. By using and applying Stem Pink Sheet analysis, traders can create a robust methodology for identifying Stem entry and exit points for their positions.
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. The companys technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Stem Cell to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Other Information on Investing in Stem Pink Sheet
Stem Cell financial ratios help investors to determine whether Stem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stem with respect to the benefits of owning Stem Cell security.